Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tromethamine is a synthetic organic amine that functions as a systemic alkalizing agent and biological buffer. It is primarily utilized to treat metabolic acidosis, especially during cardiac bypass surgery or following cardiac arrest. Unlike sodium bicarbonate, which generates carbon dioxide during the neutralization of acid, tromethamine acts as a proton acceptor, directly sequestering hydrogen ions to form bicarbonate and a cationic salt. This unique mechanism enables it to increase blood pH and decrease the partial pressure of carbon dioxide (pCO2) in both extracellular and intracellular fluids. It is administered intravenously and is particularly useful in clinical scenarios where sodium loading is undesirable, as it does not contain sodium ions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tromethamine.